Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birgit Federmann

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
Blood Advances|August 8, 2023
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphomaDiede A G van Bladel, Wendy B C Stevens, Leonie I Kroeze, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Blood|June 10, 2010
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyWolfgang A Bethge, Thoralf Lange, Christoph Meisner, et al.
Blood Advances|August 8, 2023
A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphomaDiede A G van Bladel, Wendy B C Stevens, Leonie I Kroeze, et al.
Pageof 4